Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $40.39 in the prior trading day, Protagonist Therapeutics Inc (NASDAQ: PTGX) closed at $38.65, down -4.31%. In other words, the price has decreased by -$4.31 from its previous closing price. On the day, 3.04 million shares were traded. PTGX stock price reached its highest trading level at $39.82 during the session, while it also had its lowest trading level at $33.3401.
Ratios:
Our goal is to gain a better understanding of PTGX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.91 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.05. For the most recent quarter (mrq), Quick Ratio is recorded 10.70 and its Current Ratio is at 10.70. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wedbush on November 05, 2024, initiated with a Outperform rating and assigned the stock a target price of $58.
On September 24, 2024, TD Cowen started tracking the stock assigning a Buy rating and target price of $65.
On September 09, 2024, Truist started tracking the stock assigning a Buy rating and target price of $60.Truist initiated its Buy rating on September 09, 2024, with a $60 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 15 ’24 when MOLINA ARTURO MD sold 1,906 shares for $40.98 per share. The transaction valued at 78,108 led to the insider holds 46,444 shares of the business.
Ali Asif sold 14,203 shares of PTGX for $631,872 on Sep 11 ’24. The Chief Financial Officer now owns 34,960 shares after completing the transaction at $44.49 per share. On Sep 10 ’24, another insider, Waddill William D., who serves as the Director of the company, sold 8,000 shares for $45.00 each. As a result, the insider received 360,000 and left with 12,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTGX now has a Market Capitalization of 2303462912 and an Enterprise Value of 1949342976. As of this moment, Protagonist’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.50. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.11 while its Price-to-Book (P/B) ratio in mrq is 4.32. Its current Enterprise Value per Revenue stands at 6.02 whereas that against EBITDA is 12.99.
Stock Price History:
Over the past 52 weeks, PTGX has reached a high of $48.89, while it has fallen to a 52-week low of $16.63. The 50-Day Moving Average of the stock is -14.92%, while the 200-Day Moving Average is calculated to be 8.47%.
Shares Statistics:
The stock has traded on average 601.49K shares per day over the past 3-months and 714210 shares per day over the last 10 days, according to various share statistics. A total of 57.71M shares are outstanding, with a floating share count of 56.31M. Insiders hold about 5.52% of the company’s shares, while institutions hold 100.41% stake in the company. Shares short for PTGX as of 1730332800 were 3282001 with a Short Ratio of 5.46, compared to 1727654400 on 3520031. Therefore, it implies a Short% of Shares Outstanding of 3282001 and a Short% of Float of 5.58.
Earnings Estimates
A comprehensive evaluation of Protagonist Therapeutics Inc (PTGX) is underway, with the input of 5.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.17, with high estimates of $1.92 and low estimates of -$0.61.
Analysts are recommending an EPS of between $3.71 and $1.65 for the fiscal current year, implying an average EPS of $2.41. EPS for the following year is -$1.03, with 5.0 analysts recommending between -$0.16 and -$2.42.
Revenue Estimates
7 analysts predict $61.17M in revenue for the current quarter. It ranges from a high estimate of $165M to a low estimate of $4.78M. As of the current estimate, Protagonist Therapeutics Inc’s year-ago sales were $60M
A total of 7 analysts have provided revenue estimates for PTGX’s current fiscal year. The highest revenue estimate was $428.8M, while the lowest revenue estimate was $268.57M, resulting in an average revenue estimate of $325M. In the same quarter a year ago, actual revenue was $60M
